Want to Budesonide latest news on your twitter account??? |
Santarus: A Turnaround Biotech Stock - Investorplace.com Investorplace.com--However, the story here is the company's products under development that will reach the market in the next few years � including -Budesonide- MMX, a treatment for ulcerative colitis, Rhucin, treatment for hereditary angioedema, and - Date : Mon, 12 Mar 2012 11:27:54 GMT |
Salix Pharmaceuticals (SLXP) Shares Given New $57.00 Price Target by Piper ... - LocalizedUSA LocalizedUSA--As of December 31, 2010, the Company’s primary product candidates under development include Rifaximin, Crofelemer, Balsalazide disodium tablet and -Budesonide- foam. In February 2011, the Company acquired the license to develop and co - Date : Wed, 04 Jan 2012 12:54:47 GMT |
AZ stops making Pulmicort pMDI inhaler - InPharm InPharm--The decision to stop making the 100mcg and 200mcg/dose versions of the Pulmicort (-budesonide-) pMDI product is related to "complex manufacturing issues related to technical aspects of the device", said SkyePharma in a statement - Date : Tue, 08 Mar 2011 10:10:39 GMT+00:00 |
AAAAI: Intermittent Tx Works for Wheezing Toddlers - MedPage Today MedPage Today--The frequency of asthma exacerbations requiring systemic corticosteroids did not differ for children given low-dose -budesonide- (Pulmicort) daily and those who got a seven-day, high-dose course only during respiratory tract illnesses (P=0. - Date : Thu, 24 Mar 2011 13:48:20 GMT+00:00 |
AstraZeneca to discontinue production of PULMICORT® pMDI, other respiratory ... - IEWY News IEWY News--AstraZeneca will discontinue the production of PULMICORT® (-budesonide-) 100 and 200 µg/dose HFA pMDI (pressurised metered dose inhaler) due to complex manufacturing issues related to technical aspects of the device, which prevents the ongoin - Date : Wed, 16 Mar 2011 01:32:51 GMT+00:00 |
Viral-induced asthma halted by inhaled steroid reliever - 6minutes 6minutes--Using a -budesonide--formoterol (Symbicort) inhaler as a reliever at the first signs of asthma deterioration was associated with a 52% reduction in cold-related asthma exacerbation compared to use of a short-acting beta-agonist (SABA) as a relie - Date : Fri, 18 Mar 2011 02:48:50 GMT+00:00 |
Federal Circuit affirms preliminary injunction barring defendant from ... - Lexology (registration) Lexology (registration)--AstraZeneca markets its FDA-approved -budesonide- inhalation suspension under the name PULMICORT RESPULES®. The Orange Book entry for this -budesonide- product ... - Date : Fri, 07 Jan 2011 17:22:12 GMT+00:00 |
Santarus to Webcast Analyst Day and Investor Briefing Presentation on January 19 - PR Newswire (press release) PR Newswire (press release)--Santarus also has a diverse development pipeline with three late-stage product candidates in Phase III clinical programs: ULTESA™ (-budesonide- MMX®) for ... - Date : Wed, 19 Jan 2011 09:01:55 GMT+00:00 |
Drug Market To Decline, However Revenue Earning Opportunities To Continue - Pharmaceuticals & Healthcare Insight (registration) Pharmaceuticals & Healthcare Insight (registration)--The largest pharmaceutical products by sales in 2009 included Amgen's Enbrel (etanercept), AstraZeneca's Symbicort (-budesonide- + formoterol), ... - Date : Tue, 11 Jan 2011 06:48:33 GMT+00:00 |
Opportunities For Drugmakers Will Continue - Pharmaceuticals & Healthcare Insight (registration) Pharmaceuticals & Healthcare Insight (registration)--Sales of the largest pharmaceutical products in 2009 included Amgen's Enbrel (etanercept), AstraZeneca's Symbicort (-budesonide- and formoterol), ... - Date : Sat, 08 Jan 2011 06:24:56 GMT+00:00 |